You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Anti-Fibronectin antibody [B971M] (ab104809)

Submit an Abreview Submit a Question

Overview

Properties

Applications

Our Abpromise guarantee covers the use of ab104809 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
WB WB: Use at an assay dependent dilution. Predicted molecular weight: 263 kDa.
ELISA ELISA: Use at an assay dependent dilution.

Target

  • FunctionFibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonization, wound healing, and maintenance of cell shape.
    Anastellin binds fibronectin and induces fibril formation. This fibronectin polymer, named superfibronectin, exhibits enhanced adhesive properties. Both anastellin and superfibronectin inhibit tumor growth, angiogenesis and metastasis. Anastellin activates p38 MAPK and inhibits lysophospholipid signaling.
  • Tissue specificityPlasma FN (soluble dimeric form) is secreted by hepatocytes. Cellular FN (dimeric or cross-linked multimeric forms), made by fibroblasts, epithelial and other cell types, is deposited as fibrils in the extracellular matrix. Ugl-Y1, Ugl-Y2 and Ugl-Y3 are found in urine.
  • Involvement in diseaseGlomerulopathy with fibronectin deposits 2 (GFND2) [MIM:601894]: Genetically heterogeneous autosomal dominant disorder characterized clinically by proteinuria, microscopic hematuria, and hypertension that leads to end-stage renal failure in the second to fifth decade of life. Note=The disease is caused by mutations affecting the gene represented in this entry.
  • Sequence similaritiesContains 12 fibronectin type-I domains.
    Contains 2 fibronectin type-II domains.
    Contains 16 fibronectin type-III domains.
  • Developmental stageUgl-Y1, Ugl-Y2 and Ugl-Y3 are present in the urine from 0 to 17 years of age.
  • Post-translational
    modifications    Sulfated.
    It is not known whether both or only one of Thr-2064 and Thr-2065 are/is glycosylated.
    Forms covalent cross-links mediated by a transglutaminase, such as F13A or TGM2, between a glutamine and the epsilon-amino group of a lysine residue, forming homopolymers and heteropolymers (e.g. fibrinogen-fibronectin, collagen-fibronectin heteropolymers).
    Phosphorylation sites are present in the extracellular medium.
    Proteolytic processing produces the C-terminal NC1 peptide, anastellin.
  • Cellular localizationSecreted > extracellular space > extracellular matrix.

    • Target information above from: UniProt accession P02751 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
    • Alternative names
        CIG antibodyCold insoluble globulin antibodyCold-insoluble globulin antibody
        DKFZp686F10164 antibodyDKFZp686H0342 antibodyDKFZp686I1370 antibodyDKFZp686O13149 antibodyED B antibodyFibronectin 1 antibodyFINC antibodyFINC_HUMAN antibodyFN antibodyFN1 antibodyFNZ antibodyGFND antibodyGFND2 antibodyLETS antibodyMigration stimulating factor antibodyMSF antibodyUgl-Y3 antibody
      see all

    References for Anti-Fibronectin antibody [B971M] (ab104809)

    ab104809 has not yet been referenced specifically in any publications.

    Publishing research using ab104809 ? Please let us know so that we can cite the reference in this datasheet

    Product Wall

    Submit an Abreview for ab104809 Submit a Question for ab104809

    There are currently no Abreviews or Questions for ab104809.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"